Roche cutting jobs in product development - media
Reuters
Published Feb 09, 2024 06:15
Updated Feb 09, 2024 07:25
ZURICH (Reuters) -Roche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead.
The jobs will go in the product development area, and corresponded to about 6% of the workforce in the area, Muula said.
Of the 5,800 jobs worldwide that develop pharmaceutical products or provide IT support for product development at Roche (LON:0QQ6), around 1,800 are in Switzerland, where around 100 jobs are expected to fall victim to the cost cuts, the website added.
Roche told Reuters the number of jobs affected would be less than 345 people, although the company could not provide a precise figure.
"The success and sustainable growth of our company depends on our ability to recognize innovation proactively and early on, to adapt to change and to use our resources wisely," she said.
"We expect Roche's total workforce to remain stable in 2024."
The Basel-based drugs and diagnostic maker last week reported 7% lower sales and a 9% drop in net income during 2023 as it tackled a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs.
Roche employs roughly 101,000 people globally, including 14,200 in Switzerland, according to the company's website.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.